Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Yes, studying memory formation is increasingly helping to treat dementia. Recent breakthroughs in understanding how the brain encodes and stores memories have led to concrete therapeutic approaches—from drug therapies to cognitive training—that show promise in reversing or slowing memory loss. Researchers have moved beyond simply observing what goes wrong in dementia to actually targeting the specific cellular and molecular mechanisms that underlie memory creation, opening pathways for treatment that seemed impossible just a few years ago.
The shift is happening because scientists now understand memory formation at multiple levels: the genes that activate during learning, the proteins that build connections between brain cells, the cellular structures where memories are stored, and the neural networks that retrieve them. When dementia disrupts these processes, researchers can now identify exactly where the breakdown occurs and design interventions to restore function. For example, Harvard researchers recently mapped the precise molecular changes that happen when the brain learns something new, providing a roadmap for how to reverse the memory deficits seen in Alzheimer’s disease and other forms of dementia.
Table of Contents
- How Understanding Memory Formation Mechanisms Informs Dementia Treatment
- Genetic and Molecular Breakthroughs in Memory Restoration
- Pharmaceutical Approaches to Restoring Memory and Cognitive Function
- Cognitive Training and Brain Plasticity—Direct Evidence of Prevention and Treatment
- Brain Stimulation and Metabolic Interventions
- Identifying Cellular Targets for Therapeutic Intervention
- Integrating Multiple Approaches—The Future of Dementia Treatment
- Conclusion
How Understanding Memory Formation Mechanisms Informs Dementia Treatment
memory formation begins in the hippocampus, a brain region shaped like a seahorse that sits deep inside the temporal lobe. When you learn something new, neurons in this region fire in specific patterns, releasing neurotransmitters and triggering molecular cascades that strengthen connections between cells. This process, called synaptic plasticity, is the physical basis of memory. In dementia, particularly Alzheimer’s disease, these molecular processes break down—proteins misfold and accumulate, gene expression patterns change, and connections between neurons weaken or are lost entirely. By studying how memory forms in healthy brains, researchers have identified the molecular machinery that goes wrong in dementia. Harvard scientists, publishing their findings in May 2025, developed techniques to track precisely how learning and memories are encoded at the molecular level. This detailed mapping reveals not just that memory formation fails in dementia, but exactly how and why.
With this knowledge, scientists can design drugs or genetic therapies to restore the specific molecules or processes that are broken. This represents a fundamental shift from treating dementia as a single disease to treating it as a dysfunction of specific molecular systems. Adult hippocampal neurogenesis—the birth of new neurons in the hippocampus—has emerged as a particularly important therapeutic target. The dentate gyrus, a subregion of the hippocampus, continues to generate new neurons throughout life in healthy people, and these young neurons appear crucial for forming new episodic memories (memories of events). In Alzheimer’s disease, this neurogenesis slows dramatically. Understanding this deficit has led researchers to explore therapies that stimulate the generation of new neurons as a way to restore memory-forming capacity. However, one important limitation is that most of this research remains in animal models, and the complexity of the human brain means that approaches that work in mice don’t always translate to humans.
Genetic and Molecular Breakthroughs in Memory Restoration
one of the most dramatic recent advances involves using gene-editing technology to restore lost memory function. In November 2025, scientists used CRISPR tools to correct molecular disruptions in the hippocampus and amygdala of aging rats, successfully restoring memory. They also identified and revived a silenced memory gene called IGF2 through targeted DNA methylation editing, which improved memory formation. These experiments demonstrate that memory loss due to aging isn’t necessarily permanent—the underlying machinery can be repaired if you target the right molecular switches. The significance of this work lies in its specificity. Rather than trying to broadly stimulate the brain or boost general metabolism, these approaches fix the exact problem. The IGF2 gene, when activated, supports the growth and survival of neurons and the formation of synaptic connections.
When aging or disease silences this gene, memory suffers. By reactivating it through DNA methylation editing—a technique that doesn’t alter the DNA sequence itself but changes which genes are turned on or off—researchers restored memory in animal models. This suggests that human therapies targeting similar mechanisms could be developed. A critical caveat is that these approaches have been tested primarily in aged rats or mouse models of Alzheimer’s disease, not in human patients. The gap between an animal study showing promise and a FDA-approved human therapy can span years or decades, and some approaches that work in rodents fail in humans due to differences in brain size, complexity, and how diseases progress. Additionally, delivering gene-editing tools to the brain is technically challenging—the blood-brain barrier, a protective shield that surrounds brain tissue, blocks most large molecules. Researchers are developing delivery methods, but this remains a significant hurdle to translation.
Pharmaceutical Approaches to Restoring Memory and Cognitive Function
Pharmaceutical research has produced several experimental drugs showing promise in reversing memory loss. GL-II-73, an experimental drug tested in Alzheimer’s disease mouse models, restores memory and cognitive function by improving memory deficits and reversing brain cell damage. Another drug, NU-9, developed through 2025 research, takes a different approach—it targets a particularly toxic form of amyloid beta, the protein fragments that accumulate in Alzheimer’s disease brains. By decreasing these toxic oligomers, NU-9 dramatically reduced brain cell damage in mouse models. Additionally, researchers have identified a natural aging-related molecule that repairs key memory processes affected by Alzheimer’s disease, leading to experimental treatments that show promise in reversing memory loss in early Alzheimer’s patients. The advantage of targeting natural, aging-related molecules is that the body already produces them, and drugs that enhance these molecules may have fewer side effects than entirely synthetic compounds.
These different approaches—one targeting brain cell repair, another targeting toxic protein species, a third enhancing natural repair molecules—show that memory restoration can be approached from multiple angles. The limitation here is timing and progression. Most of these drugs show the strongest effects in early-stage disease or in mouse models where the disease hasn’t yet caused irreversible brain atrophy. Once brain tissue has died, no drug can restore it. This emphasizes the importance of early detection and diagnosis, which is why the FDA’s approval of the first blood test for Alzheimer’s disease marks such an important advance. A simple blood test that detects specific forms of tau and amyloid proteins can identify people with Alzheimer’s pathology before they develop obvious memory problems, potentially allowing drug treatment to start before substantial brain damage occurs.
Cognitive Training and Brain Plasticity—Direct Evidence of Prevention and Treatment
Among the most striking recent findings is that targeted cognitive training can provide long-lasting protection against dementia. Research published in 2026 shows that speed of processing training—intensive sessions focused on improving how quickly the brain processes visual information, lasting just 5 to 6 weeks—reduced dementia risk for up to 20 years in study participants. This isn’t a marginal benefit; it demonstrates that structured cognitive intervention can have effects that persist for decades. Another approach, online brain training using the BrainHQ app administered over 10 weeks, strengthened brain networks responsible for learning and memory in older adults. Remarkably, this training reversed 10 years of aging in memory and learning capacity, with significant improvements in cholinergic function—a brain system critical for attention and memory. These aren’t just laboratory improvements; they represent measurable restoration of the neural systems that form and retrieve memories.
The advantage of cognitive training is that it’s non-invasive, accessible, and works with the brain’s natural capacity for neuroplasticity—the ability to rewire itself through experience. However, cognitive training has limitations. It works best for people with mild cognitive impairment or those at risk for dementia, not for people with advanced dementia where significant brain tissue has already been lost. Additionally, the gains require ongoing engagement; the brain benefits from learning and mental challenge, but those benefits can diminish if training stops. Cognitive training also works better for some people than others, and access to quality programs remains unequal. The 20-year protection from speed of processing training is powerful, but it required initial commitment and effort, and the study didn’t capture how many people started the program but didn’t complete it.
Brain Stimulation and Metabolic Interventions
Researchers are also exploring whether directly stimulating the brain can enhance memory. Electrical brain stimulation combined with exercise is being studied as an approach to improve memory in dementia patients through federally-funded research. The rationale is that brain stimulation can enhance the brain’s capacity to form new connections, while exercise increases blood flow and growth factors to the brain. Together, these might restore memory networks that have weakened due to disease. Metabolic therapies represent another frontier. Metabolic brain boost therapies have shown promise in restoring memory in animal models, with drugs that enhance brain metabolism potentially able to reverse some Alzheimer’s symptoms. The logic is that Alzheimer’s disease involves metabolic dysfunction—the brain’s cells become energy-starved and can’t maintain the intensive metabolic demands of memory formation.
By boosting this energy system, researchers hope to restore memory function. This approach targets a fundamental problem (energy deficit) that underlies multiple other deficits in the disease. One important warning about these newer approaches is that they’re still largely in research phases. Electrical brain stimulation in humans requires implanted devices, which carries surgical risks and isn’t practical for all patients. Metabolic therapies based on these animal studies may not translate to humans as effectively as researchers hope. These approaches should be understood as promising directions under investigation, not established treatments. For people with dementia today, cognitive approaches and existing medications offer more established benefits, though the field is moving rapidly toward more targeted therapies.
Identifying Cellular Targets for Therapeutic Intervention
Beyond the broad systems of memory formation, researchers have identified specific cellular components that could be targeted therapeutically. Type 4 serotonin receptors in the hippocampus have emerged as a potential therapeutic target for learning and memory impairments. Serotonin is a neurotransmitter involved in mood, learning, and other functions. By targeting specific serotonin receptors, researchers hope to enhance the brain’s capacity for learning and memory formation.
These highly specific targets represent the next generation of dementia treatment. Rather than drugs that broadly affect the entire brain, future therapies will likely target particular receptor types or molecular pathways. This specificity could reduce side effects while maximizing therapeutic benefit. The challenge is that these targets are being identified in basic research; translating them into clinical drugs is a process that typically takes many years and billions of dollars.
Integrating Multiple Approaches—The Future of Dementia Treatment
The most exciting possibility emerging from all this research is that treatments targeting different aspects of memory formation can be combined. Someone at risk for dementia might benefit from cognitive training to enhance memory networks, medications to reduce toxic protein accumulation, drugs that boost brain metabolism, and potentially brain stimulation or other therapies—used together in a personalized approach based on their specific disease stage and biology. The blood test for Alzheimer’s disease allows early identification, when interventions can be most effective.
The field is shifting from a model where dementia is treated as an inevitable consequence of aging to one where it’s viewed as a treatable dysfunction of specific brain systems. As understanding of memory formation deepens, so does the toolkit for restoring it. While no current treatment cures dementia or fully restores lost memories, the trajectory is unmistakably toward more effective interventions, earlier detection, and eventual prevention.
Conclusion
Studying memory formation is directly enabling the development of new treatments for dementia. From CRISPR gene editing that reactivates memory-related genes, to pharmaceutical approaches that clear toxic proteins or boost cellular energy, to cognitive training that reverses a decade of cognitive aging, understanding how memories form in healthy brains reveals exactly what goes wrong in disease and how to fix it. These aren’t theoretical possibilities—they’re approaches currently in clinical trials or showing real benefits in studies.
For someone concerned about dementia risk or facing a diagnosis, the message from this research is that memory loss isn’t simply an inevitable part of aging. Multiple avenues now exist to prevent, slow, or potentially reverse memory decline, particularly in early stages. Staying cognitively active, maintaining brain health through exercise and metabolic support, and consulting with a healthcare provider about emerging therapies and diagnostic testing represent practical steps grounded in this emerging science.
You Might Also Like
- Can Supplements Help or Hurt Brain Health?
- Why Brain Health Marketing Can Mislead Families
- What Memory Protein Research Means for Brain Science
Related reading
- how Long-Term Memories May Depend on Alzheimer’s-Related Biology
- could Blocking the Wrong Protein Hurt Memory
- why Alzheimer’s Drug Design Must Be Precise
- what Brain Proteins Teach Us About Memory Loss
- could Immune Cells Drive Alzheimer’s Progression
For more on this topic, see NIH MedlinePlus — cognitive testing.
